Biochemistry of glycosphingolipid storage disorders: implications for therapeutic intervention
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The physiological importance of the degradative processes in lysosomes is revealed by the existence of at least 40 distinct inherited diseases, the so–called lysosomal storage disorders. Most of these diseases are caused by a deficiency in a single lysosomal enzyme, or essential cofactor, and result in the lysosomal accumulation of one, or sometimes several, natural compounds. The most prevalent subgroup of the lysosomal storage disorders is formed by the sphingolipidoses, inherited disorders that are characterized by excessive accumulation of one or multiple (glyco)sphingolipids. The biology of glycosphingolipids has been extensively discussed in other contributions during this symposium. This review will therefore focus in depth on (type 1) Gaucher disease, a prototypical glycosphingolipidosis. The elucidation of the primary genetic defect, being a deficiency in the lysosomal glucocerebrosidase, is described. Characterization of glucocerebrosidase at protein and gene level has subsequently opened avenues for therapeutic intervention. The development of successful enzyme replacement therapy for type 1 Gaucher disease is discussed. Attention is also paid to the alternative approach of substrate modulation using orally administered inhibitors of glucosylceramide synthesis. Novel developments about the monitoring of age of onset, progression and correction of disease are described. The remaining challenges about pathophysiology of glycosphingolipidoses are discussed in view of further improvements in therapy for these debilitating disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of lysosomal storage disorders
Meikle, P. J. (1999) · JAMA · doi:10.1001/jama.281.3.249 · Cited by 2,197
Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.
Hollak, C. E., van Weely, S., van Oers, M. H., & Aerts, J. M. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117084 · Cited by 896
Self-citationStahl, P. D., Rodman, J. S., Miller, M. J., & Schlesinger, P. H. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.3.1399 · Cited by 590
Linehan, S. A., Martínez-Pomares, L., Stahl, P. D., & Gordon, S. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.12.1961 · Cited by 285
Cited by
The many faces of the adamantyl group in drug design
Liu, J., Obando, D., Liao, V., Lifa, T., & Codd, R. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.01.047 · Cited by 309
Characterization of human phagocyte-derived chitotriosidase, a component of innate immunity
van Eijk, M., van Roomen, C. P. A. A., Renkema, G. H., Bussink, A. P., Andrews, L., Blommaart, E. F. C., Sugar, A., Verhoeven, A. J., Boot, R. G., & Aerts, J. M. F. G. (2005) · International Immunology · doi:10.1093/intimm/dxh328 · Cited by 305
Self-citationPharmacological Inhibition of Glucosylceramide Synthase Enhances Insulin Sensitivity
Aerts, J. M., Ottenhoff, R., Powlson, A. S., Grefhorst, A., van Eijk, M., Dubbelhuis, P. F., Aten, J., Kuipers, F., Serlie, M. J., Wennekes, T., et al. (2007) · Diabetes · doi:10.2337/db06-1619 · Cited by 301
Self-citationGaucher disease: pathological mechanisms and modern management
Jmoudiak, M., & Futerman, A. H. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05351.x · Cited by 288
Plasma chitotriosidase and CCL18: Early biochemical surrogate markers in type B Niemann‐Pick disease
Brinkman, J., Wijburg, F. A., Hollak, C. E., Groener, J. E., Verhoek, M., Scheij, S., Aten, J., Boot, R. G., & Aerts, J. M. (2005) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-005-4416-9 · Cited by 90
“The experience with Gaucher disease has demonstrated the importance of surrogate markers of disease that can assist in clinical decision making (Aerts et al 2003; Hollak et al 2001).”
BackgroundSelf-citationVan der Lienden, M. J. C., Gaspar, P., Boot, R., Aerts, J. M. F. G., & Van Eijk, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010066 · Cited by 84
“There is no strict correlation between mutations in GBA and disease manifestation in GD patients [8,9].”
BackgroundSelf-citationTol, M. J., van der Lienden, M. J. C., Gabriel, T. L., Hagen, J. J., Scheij, S., Veenendaal, T., Klumperman, J., Donker-Koopman, W. E., Verhoeven, A. J., Overkleeft, H., et al. (2018) · Autophagy · doi:10.1080/15548627.2017.1419118 · Cited by 27
“As a result, lysosomal dysfunction has been coupled to a wide range of inherited [5-7] and acquired meta-”
BackgroundSelf-citation
Metadata
- Authors
- Aerts, J. M., Hollak, C., Boot, R., & Groener, A.
- Venue
- Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences
- Publisher
- The Royal Society
- Published
- 2003-05-29
- Volume
- 358
- Issue
- 1433
- Pages
- 905-914
- ISSN
- 0962-8436 (ISSN-L)
- 1471-2970
- OpenAlex
- W2097972170
- Cited by
- 72
- References
- 4
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.